Skip header and navigation

56 records – page 1 of 6.

Document Type
Rapid Review
Review Code
EOC040201 RR
Question Submitted
April 7, 2020
Date Completed
April 7, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC040201 RR
Question Submitted
April 7, 2020
Date Completed
April 7, 2020
Status
3. Completed
Research Team
EOC
Key Findings
Most large scale studies quantifiying the rate of sore throat in COVID cases is under 10%, with some exceptions of small scale studies.
Only one study comparing COVID (7% incidence of sore throat) to non-COVID patients (23% incidence of sore throat)
Category
Clinical Presentation
Subject
Symptoms
Population
All
Priority Level
Level 1 completed within 4 hours
Cite As
Badea, A; Groot, G; Dalidowicz, M; Young, C; Miller, L. What is the prevalence of sore throat as a symptom of COVID-19? 2020 Apr 7; Document no.: EOC040201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 8 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC032401-01 ESR
Question Submitted
March 24, 2020
Date Completed
March 24, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC032401-01 ESR
Question Submitted
March 24, 2020
Date Completed
March 24, 2020
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Immunity
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Dalidowicz, M. What is the risk of reinfection from COVID-19? 2020 Mar 24; Document no.: EOC032401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 3 p. (CEST evidence search report)
Review History
EOC032401v2 RR: August 1, 2020
EOC032401 RR: May 14, 2020
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC040201-01 ESR
Question Submitted
April 7, 2020
Date Completed
April 7, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC040201-01 ESR
Question Submitted
April 7, 2020
Date Completed
April 7, 2020
Status
3. Completed
Research Team
EOC
Category
Clinical Presentation
Subject
Symptoms
Population
All
Priority Level
Level 1 completed within 4 hours
Cite As
Dalidowicz, M; Young, C; Miller, L. What is the prevalence of sore throat as a symptom of COVID-19? 2020 Apr 7; Document no.: EOC040201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Antibodies
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 14; Document no.: LAB041401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 15; Document no.: LAB041501-01 ESR In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PPE041701 RR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE041701 RR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
The most commonly reported symptoms inCOVID-19patientswere: fever (79-89%); cough (58-69%); fatigue/muscle aches (29-36%); dyspnea (22-38%); chest distress (31%); and expectoration (12-29%).
Less common were various GI symptoms (9-18%) including diarrhea (5-7%) and nausea (4%),as well as sore throat (10-12%) and headache (6-12%).
Although the Government of Canada lists runny nose as a potential symptom for a suspect case, it was not reported as such in the meta-analyses examined.
Category
Clinical Presentation
Subject
Natural History
Symptoms
Screening
Priority Level
Level 2 completed within 8 hours
Cite As
McCarron, M; Groot, G; Dalidowicz, M; Miller, L. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 17; Document no.: PPE041701 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PPE041701-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Evidence Search Report
Review Code
PPE041701-01 ESR
Question Submitted
April 17, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Category
Clinical Presentation
Subject
Natural History
Symptoms
Screening
Priority Level
Level 2 completed within 8 hours
Cite As
Miller, L; Dalidowicz, M. What distinguishes COVID-19 from influenza-like illnesses? 2020 Apr 16; Document no.: PPE041701-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail

56 records – page 1 of 6.